This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study.
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study of Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited, India comparing with that of SINGULAIR® (Montelukast sodium) 4mg oral granules of Merck Sharp \& Dohme Ltd., USA in healthy, adult, human subjects under fed conditions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
31
Montelukast Sodium Oral Granules 4mg
AXIS Clinicals Limited,
Hyderabad, Andhra Pradesh, India
Area under curve(AUC)
Time frame: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 8.50, 9.00, 12.00, 16.00, 20.00 and 24.00 hours post dose.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.